Form 4: Polaris Partners Reports Common Stock Transactions Following Camp4 Therapeutics IPO

Polaris Partners and related entities report the conversion of preferred stock to common stock and the purchase of additional common stock following Camp4 Therapeutics' initial public offering.

Summary

• Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C., and Amy Schulman filed a Form 4 regarding changes in beneficial ownership of Camp4 Therapeutics Corp [CAMP] stock on October 15, 2024.
• The filing reflects transactions related to the automatic conversion of Series A Prime Convertible Preferred Stock and Series B Preferred Stock into common stock upon the closing of Camp4 Therapeutics' IPO.
• The Series A Prime Convertible Preferred Stock converted at a rate of 11.2158 shares of common stock for each share of preferred stock.
• Similarly, the Series B Preferred Stock converted at a rate of 11.2158 shares of common stock for each share of preferred stock.
• Polaris Partners X, L.P. also purchased 909,090 shares of common stock at a price of $11 per share.
• The filing details the indirect ownership of the shares by various Polaris entities and managing members, who disclaim beneficial ownership except to the extent of their pecuniary interests.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The conversion of preferred stock is a standard part of the IPO process, and the purchase of additional shares indicates continued confidence from a major investor. However, the document itself is purely informational and doesn't contain explicit positive or negative statements.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Camp4 Therapeutics following its IPO.
• Polaris Partners' purchase of additional common stock at $11 per share demonstrates continued investment in the company.

Future Outlook

The document does not contain specific forward-looking statements regarding Camp4 Therapeutics' future performance.

Industry Context

Form 4 filings are standard practice after an IPO, providing transparency into the ownership changes resulting from the event and any subsequent transactions by significant shareholders.

Stakeholder Impact

• The conversion of preferred stock to common stock may impact the ownership structure and voting rights of existing shareholders.
• The purchase of additional shares by Polaris Partners could be viewed positively by the market, potentially influencing the stock price.

Key Dates